iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutic...( Study Includ...)

Study Includes iCardiac's Highly Automated QT(sm) Solution

Rochester, New York (PRWEB) April 1, 2009 -- iCardiac Technologies announced today that its advanced cardiac safety biomarkers were used successfully in a clinical study to model the effect of a serious disease on the heart's repolarization process.

The repolarization biomarkers, captured on a continuous electrocardiogram, played a key role in helping a leading pharmaceutical company to model the effects of disease on cardiac repolarization. The information provided by iCardiac's advanced morphological biomarkers enables drug developers to separate reliably the cardiac effects triggered by experimental drugs.

"This is an important step for cardiac safety testing," said iCardiac's Co-Founder and Executive Vice President Sasha Latypova. "Up until now there has not been a means for pharmaceutical companies to separate conclusively QT prolongation that originates with the disease state from that which stems from the drug being tested."

iCardiac's advanced ECG-based biomarkers enable a comprehensive evaluation of cardiac repolarization morphology and dynamics. The repolarization process - represented by what is called the QT interval, as measured on an ECG - is the brief period of time between two heart beats and is known to be a vulnerable time for arrhythmia induction. In rare instances, drug-induced arrhythmias can lead to sudden cardiac death.

iCardiac's COMPAS software platform performs digital quantification of repolarization abnormalities and enables measurement of subtle differences in ECG signals that may indicate arrhythmia predisposition. iCardiac's validation studies conducted at the University of Rochester have demonstrated that quantification of such morphological changes complement and improve upon information gathered from QT interval studies.

The study also incl
'/>"/>